Orchiectomy¶
Bilateral removal of the testes. The simplest gender-affirming genital procedure, and the only one that can be done standalone — many people choose orchiectomy without progressing to vaginoplasty, either because they don't want a canal, can't afford one, or want the HRT-management benefits without committing to a much larger operation.
It is also the only SRS procedure that meaningfully changes hormone management afterward. Anti-androgens become unnecessary; estrogen dose typically drops by roughly half; gonadotropins and bone density become ongoing monitoring concerns. See Reference Levels for post-orchi target ranges.
For broader patient-selection and timing considerations, see Candidacy & Timing. For the larger operation that orchiectomy is sometimes a step toward, see Penile-Inversion Vaginoplasty.
Sterilization is permanent
Bilateral orchiectomy is irreversible. Sperm cryopreservation, if biological children using your gametes are a future goal, must happen before surgery. Long-term feminizing HRT severely impairs spermatogenesis; older "stop HRT for 3–6 months before banking" guidance is not reliably effective. WPATH SOC v8 explicitly requires fertility-preservation counseling before any gonadectomy.
Why people choose it¶
Reported indications in transfeminine populations:
- Eliminate the need for systemic anti-androgens — particularly when the current drug is causing problems (hyperkalemia on spironolactone; hepatotoxicity, hyperprolactinemia, or meningioma risk on cyproterone; hepatotoxicity on bicalutamide).
- Reduce the required estradiol dose by roughly 30–50% while maintaining feminizing serum levels.
- Definitive option for patients who don't want vaginoplasty or who are medically unsuitable for it.
- Cost and insurance access — orchi is an order of magnitude cheaper than vaginoplasty and is more often covered.
- Staged step before later vaginoplasty for patients who want anti-androgen cessation now and the canal later.
Regret data are reassuring. The Bustos et al. (2021) meta-analysis of gender-affirming surgery overall found pooled regret around 1%; orchiectomy specifically tracks at the low end of that range across published case series and registry data, including the Wiepjes et al. Amsterdam cohort.
Surgical technique¶
Three meaningful technique distinctions for transfeminine patients:
| Technique | What it does | Use in transfeminine care |
|---|---|---|
| Scrotal-sparing simple orchi | Testes and cords fully removed via midline (median raphe) incision; scrotal skin and dartos preserved intact | Standard of care if vaginoplasty is even possibly on the table later |
| Simple inguinal orchi | Standard urologic approach via inguinal incision | Relatively contraindicated if vaginoplasty is planned — inguinal scarring complicates later spermatic-cord access |
| Subcapsular orchi | Tunica albuginea opened, seminiferous and Leydig tissue enucleated, tunica shell preserved | Rare in transfeminine care: most patients don't want palpable remnants, and residual Leydig function can blunt the HRT benefit |
The dominant choice is a midline scrotal-sparing simple orchi: a single median-raphe incision, doubly ligated cord, tunica vaginalis excised or everted, no scrotal skin removed. The "empty sac" can later be used for labia majora flaps.
Anesthesia¶
| Anesthesia | When it's used |
|---|---|
| Local + IV sedation (MAC) | Spermatic-cord block plus local field block. Common with high-volume ambulatory surgeons (Crane, Brassard, Bowers offices have all reported MAC protocols). Lower cost, faster recovery, no airway instrumentation. |
| General | Standard at hospital-based centers; preferred when patient anxiety is high or anatomy is unusual. |
| Spinal/regional | Occasionally used; uncommon in US ambulatory practice. |
Operative time is typically 30–60 minutes bilaterally.
Effect on future vaginoplasty¶
Standalone orchi does not preclude later vaginoplasty, but the technique choice and the interval matter:
| Tissue | Used in vaginoplasty for | Affected by prior orchi? |
|---|---|---|
| Penile shaft skin | Vaginal canal lining (penile inversion) | Unchanged |
| Scrotal skin | Labia majora; sometimes graft for canal | Preserved if scrotal-sparing technique used |
| Glans penis | Neoclitoris | Unchanged |
| Urethral mucosa | Vestibular lining | Unchanged |
| Spermatic cord remnants | Removed in vaginoplasty anyway | Already gone |
Most vaginoplasty surgeons want at least 6–12 months between orchi and vaginoplasty for scrotal skin to soften and scarring to mature. Median-raphe scarring from a scrotal-sparing orchi is well within what they're used to working around and does not typically degrade outcomes.
Inguinal and subcapsular orchi compromise vaginoplasty
If there's any chance you'll want vaginoplasty later, insist on a midline scrotal-sparing simple orchi. Inguinal scars complicate spermatic-cord access during vaginoplasty. Subcapsular orchi leaves Leydig tissue that can produce enough residual androgen to blunt the HRT benefit and isn't well-studied in transfeminine cohorts.
HRT changes after orchiectomy¶
The endocrine logic: with the testes gone, the only remaining androgen source is adrenal (DHEA → peripheral conversion), which yields T levels well below the upper end of the female reference range without further suppression. Anti-androgens become unnecessary, and the estrogen dose required drops sharply because pre-orchi doses were often supraphysiologic specifically to suppress LH-driven testicular T.
Anti-androgen discontinuation¶
| Drug | Post-orchi action | Why |
|---|---|---|
| Spironolactone | Stop or taper over 1–2 weeks | No remaining androgen to block; ongoing use risks hyperkalemia, hypotension, polyuria with no benefit |
| Cyproterone acetate | Stop immediately | Removes hepatotoxicity, hyperprolactinemia, and meningioma risk |
| Bicalutamide | Stop immediately | AR blockade is moot without androgen production |
| GnRH agonist (leuprolide) | Stop at next due date | Pituitary axis no longer relevant for androgen suppression |
| Finasteride / dutasteride | Optional — patient preference | Substrate (T) is now minimal; some continue for scalp hair |
This is consistent with both the Endocrine Society 2017 guideline (Hembree et al.) and UCSF Transgender Care guidelines.
Estrogen dosing¶
- Most clinicians reduce the estradiol dose by 30–50% after orchi.
- The new target is replacement-level estradiol, not LH-suppressing estradiol. Common goal: serum E2 around 100–200 pg/mL (≈ 370–730 pmol/L), in line with mid-cycle to luteal-phase female ranges. Some clinicians aim lower (50–150 pg/mL) for bone protection plus feminization, particularly in older patients or those with cardiovascular risk.
- Estradiol monotherapy (oral, transdermal, injection, or implant) is generally sufficient. Transdermal is often preferred long-term because it avoids first-pass hepatic effects on coagulation factors — a relevant concern for patients staying on HRT for decades.
Pituitary feedback¶
LH and FSH rise post-orchi because testicular feedback is gone. With adequate estradiol, LH typically settles to suppressed or low-normal; FSH often runs higher because estradiol is a less potent suppressor of FSH than inhibin B (which the testes had been producing). Persistently very high FSH on otherwise adequate estradiol is generally not actionable — it reflects loss of inhibin, not insufficient estrogen.
Symptoms matter as much as numbers. Hot flashes, mood changes, fatigue, or low libido on apparently "adequate" estradiol can indicate the dose needs adjustment despite labs looking fine.
Bone density¶
Estrogen is the dominant sex steroid for bone maintenance in both sexes. Adequate post-orchi estradiol is protective; suboptimal estradiol after orchi is a real BMD risk because the testicular contribution to bone is now also gone.
Suggested monitoring (Endocrine Society 2017 and informal practice):
- Baseline DXA around the time of orchi, especially with risk factors (low BMI, family history, smoking, alcohol, glucocorticoids, anorexia history).
- Repeat DXA every 2–3 years if normal; sooner if borderline.
- Adequate calcium (~1000–1200 mg/day) and vitamin D intake.
- Patients who stop HRT after orchi (rare but happens) face accelerated bone loss similar to surgical menopause and should be counseled accordingly.
Long-term (>10-year) BMD outcomes specifically in transfeminine post-orchi patients on stable estradiol monotherapy are sparse. Most data come from short- and medium-term cohorts (Wiepjes et al. Amsterdam; T'Sjoen et al. endocrinology review) and are extrapolated from cisgender postmenopausal and male-hypogonadism literature.
Suggested monitoring cadence¶
| Timeframe | Tests |
|---|---|
| 6–8 weeks post-op | Estradiol, total T, LH, FSH, electrolytes (off spiro), CMP |
| 3–6 months | Estradiol, T; repeat as needed to dial in dose |
| Annually | Estradiol, T, lipids, CMP, prolactin if symptomatic |
| Every 2–3 years | DXA (especially with risk factors) |
Recovery¶
| Phase | What to expect |
|---|---|
| Day 0–2 | Scrotal swelling and bruising; mild–moderate pain controlled with NSAIDs ± a short opioid course. Ice and snug scrotal support. |
| Day 3–7 | Most patients return to desk work and light activity. Pain manageable on NSAIDs alone. |
| Week 1–2 | Walking and ADLs unrestricted; no heavy lifting or vigorous exercise. |
| Week 2–4 | Gradual return to exercise. Avoid sitting astride (cycling, horseback) until cleared. |
| Week 6–8 | Full healing. Cleared for all activity including penetrative sex if relevant. Median-raphe scar fades over 6–12 months. |
Sutures are usually absorbable. Showering is typically allowed within 24–48 hours; tub bathing and swimming are delayed 2–3 weeks.
Risks and complications¶
Reported rates draw from urologic and gender-surgery series; not all are transfeminine-specific.
| Complication | Approximate rate | Notes |
|---|---|---|
| Scrotal hematoma | ~1–5% | Most common complication; small ones resolve, large ones may need drainage |
| Surgical site infection | ~1–3% | Usually superficial; oral antibiotics |
| Wound dehiscence | ~1–2% | More common with early activity; usually heals secondarily |
| Chronic scrotal/groin pain | ~1–2% | Genitofemoral or ilioinguinal nerve irritation |
| Cosmetic dissatisfaction with empty scrotum | Variable | Some patients later request scrotectomy or vaginoplasty |
| VTE | <1% | Lower than vaginoplasty; HRT often held briefly perioperatively per surgeon |
| Regret | <1–2% | Among the lowest of any gender-affirming surgery |
There is no meaningful risk of testicular cancer recurrence (the tissue is gone) and no need for ongoing testicular self-exam.
Cost and insurance¶
Self-pay range in the US: roughly \(2,000–\)8,000 USD all-in. The lower end (\(2–4K) is typical for office-based local-anesthesia procedures; the higher end (\)5–8K) is typical for hospital-based general-anesthesia procedures or higher-cost markets. International (Thailand, Mexico) bundles often run \(1,500–\)3,000. Vaginoplasty self-pay is typically \(20,000–\)60,000, an order of magnitude more.
Orchiectomy is more often covered than vaginoplasty by US private insurance and Medicaid (in expansion states), for three reasons:
- Lower absolute cost invites less push-back.
- Cleaner medical-necessity framing — anti-androgen intolerance (hyperkalemia, hepatotoxicity, hyperprolactinemia, meningioma risk) provides justification beyond gender dysphoria alone.
- CPT 54520 (simple orchi) and 54522 (partial) are well-established urologic codes used in cisgender testicular- and prostate-cancer care, and rarely flagged.
Documentation typically requires a single WPATH-style readiness letter (vs two for vaginoplasty under SOC v7/v8), persistent gender-dysphoria documentation, and hormone-therapy history. Medicare has covered gender-affirming orchiectomy on a case-by-case basis since the 2014 NCD update. Some patients pursue orchi via insurance as a step, then self-pay or re-authorize for vaginoplasty later.
The empty-scrotum problem
Scrotal skin doesn't shrink immediately after the testes are removed; retraction takes weeks to months and is sometimes incomplete. Some patients find the empty sac distressing. Surgeons preserve scrotal skin specifically to keep vaginoplasty options open — but if you're sure you don't want vaginoplasty, ask about a scrotectomy at the time of orchi or as a small follow-up procedure.
What to ask in consult¶
| Question | Why it matters |
|---|---|
| Scrotal-sparing midline approach? | Should be the default unless you've definitively ruled out vaginoplasty. |
| Local + sedation (MAC) or general? | Both are reasonable; MAC is faster and cheaper if the surgeon is high-volume in it. |
| Who manages my HRT changes, and when? | Surgeon, endocrinologist, or PCP — should be settled before surgery, not after. |
| When do I stop my anti-androgen? | Usually the day of surgery; spironolactone may be tapered. |
| Sperm cryopreservation timeline? | If banking, do it before surgery; intraoperative TESE is technically possible but lower-yield on suppressed testes. |
| If I might want vaginoplasty later, what interval do you recommend? | 6–12 months is typical. |
| What's your hematoma rate and management threshold? | Most common complication; drainage threshold should be specific. |
Sources¶
- Hembree WC, et al. (2017) — Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline (J Clin Endocrinol Metab) — anti-androgen cessation and post-gonadectomy estrogen dosing.
- Coleman E, et al. (2022) — WPATH Standards of Care v8 (Int J Transgend Health) — fertility-preservation counseling and readiness criteria for gonadectomy.
- Bustos VP, et al. (2021) — Regret after Gender-affirmation Surgery: A Systematic Review and Meta-analysis of Prevalence (Plast Reconstr Surg Glob Open) — pooled ~1% regret across gender-affirming procedures.
- Wiepjes CM, et al. (2018) — The Amsterdam Cohort of Gender Dysphoria Study (1972–2015): Trends in Prevalence, Treatment, and Regrets (J Sex Med) — large long-term cohort with regret and outcome data.
- Wiepjes CM, et al. (2017) — Bone Mineral Density Increases in Trans Persons After 1 Year of Hormonal Treatment (J Bone Miner Res) — BMD trajectory on feminizing HRT.
- T'Sjoen G, et al. (2019) — Endocrinology of Transgender Medicine (Endocr Rev) — post-gonadectomy hormonal management overview.
- UCSF Center of Excellence for Transgender Health (2016) — Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People, 2nd ed. — practical post-orchi anti-androgen and estrogen guidance.
- Adeleye AJ, et al. (2019) — Semen parameters among transgender women with a history of hormonal treatment (Urology) — fertility-preservation outcomes after HRT.
- Barnard EP, et al. (2019) — Fertility Preservation Outcomes in Adolescent and Young Adult Feminizing Transgender Patients (Pediatrics).
- Defreyne J, et al. (2019) — Effects of gender-affirming hormones on lipid, metabolic, and cardiac surrogate blood markers in transgender persons (Clin Chem) — post-orchi estrogen dose and cardiometabolic surrogates.
- Hadj-Moussa M, et al. (2018) — Feminizing Genital Gender-Confirmation Surgery (Sex Med Rev) — staged orchi prior to vaginoplasty.
- Centers for Medicare & Medicaid Services (2016) — Decision Memo for Gender Dysphoria and Gender Reassignment Surgery (CAG-00446N) — Medicare coverage framework.
- AMA CPT codes 54520 (simple orchiectomy) and 54522 (partial orchiectomy).